The SPDR S&P Biotech ETF (XBI) closed at $165.71 on August 22, 2026, adding 1.43% over the prior 24 hours as the fund extended a notable stretch of gains.
Over the past seven days, XBI has advanced 5.27%, reflecting sustained buying interest in the biotech sector. The monthly picture is similarly constructive, with the fund up 8.96% over the trailing 30-day period.
XBI tracks an equal-weighted index of biotechnology companies listed in the S&P Total Market Index, giving smaller-cap names meaningful representation alongside larger biotech firms. The structure can amplify both gains and losses relative to market-cap-weighted alternatives.
Market capitalization data for the fund was not available at the time of publication.
